Drugs / SCTV01E-2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05933512 | Aug → Dec 2023 | COVID-19 | Sinocelltech Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCTV01E-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05933512 ↗ |
| Known as | S-Trimer Vaccine | “SCTV01E-2 (COVID-19 Beta/Omicron (BA.1/BQ.1.1/XBB.1) Variants S-Trimer Vaccine)” NCT05933512 ↗ |
| Modality | Vaccine | “A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E-2 (COVID-19 Beta/Omicron (BA.1/BQ.1.1/XBB.1) Variants S-Trimer Vaccine) in Population Previously...” NCT05933512 ↗ |
| Route | Intramuscular | “intramuscular injection” NCT05933512 ↗ |